期刊文献+

5-氧-烯丙基-2,3,4-三-氧-苄基-D-核糖醇的合成工艺改进

Improved synthesis of 5-allyloxy-2,3,4-tris(benzyloxy) pentan-1-ol
下载PDF
导出
摘要 目的合成5-氧-烯丙基-2,3,4-三-氧-苄基-D-核糖醇。方法以D-核糖为原料,经甲苷化、苄基化、水解、肟保护、烯丙基化、脱肟、还原7步反应得到5-氧-烯丙基-2,3,4-三-氧-苄基-D-核糖醇。结果与讨论总收率55%,目标产物结构经核磁共振氢谱确认。该合成路线步骤少,绿色环保,适合工业化生产。 Objective To synthesize 5 - allyloxy - 2,3,4 - tris(benzyloxy)pentan - 1 - ol. Methods With D - ri-bose as the starting material,5 - allyloxy - 2,3,4 - tris(benzyloxy)pentan - 1 - ol was obtained by glycosidation,benzyla-tion,hydrolyzation,oxime protection,allylation,deoximation and reduction. Results and Conclusion The overall yield of this method was 55% ,and the structure of product was characterized by 1H - NMR. The synthetic route was short and envi-ronmentally friendly,suitable for the industrial production.
出处 《药学研究》 CAS 2015年第12期741-743,共3页 Journal of Pharmaceutical Research
关键词 5-氧-烯丙基-2 3 4-三-氧-苄基-D-核糖醇 合成 抗体 核糖-核糖醇 5-Allyloxy-2,3,4-tris(benzyloxy) pentan-1-ol Synthesis Antibody Ribose-ribitol
  • 相关文献

参考文献8

  • 1吴昕,贾作民,黎明强.Hib感染性疾病的免疫预防[J].微生物学免疫学进展,2006,34(4):76-80. 被引量:3
  • 2袁曾麟,李凤祥,李亚楠,石继春.我国人群中抗b 型流感嗜血杆菌多糖抗体水平的调查[J].中华流行病学杂志,1999,20(1):42-44. 被引量:33
  • 3林云.b型流感杆菌结合疫苗[J].国外医学(预防.诊断.治疗用生物制品分册),2005,28(5):200-202. 被引量:1
  • 4王燕,王秉瑞,谢贵林.结合疫苗概述[J].微生物学免疫学进展,2000,28(1):60-63. 被引量:4
  • 5BencomoVV,RoyR.Oligosaccharidesderivedfromribose-ribitol-phoaphate,andvaccinescontainingthem:US,6765091[P].2004-7-20.
  • 6JustG,UpeslacisJ.Novelpolysaccharidesnovelmacromolecularconjugatesofthepolysaccharides:EP,0320942[P].1989-6-21.
  • 7BeuveryEC,EvenbergA,PoolmanJT,etal.Oligoshaccharides,immunogensandvaccines,andmethodsforpreparingsuchOligoshaccharides,immunogensandvaccines:US,5034519A[P].1991-7-23.
  • 8VicenteG,ReneR.Oligosaccharidesderivedfromribose-ribitol-phosphate,andvaccinescontainingthem:US,6765091[P].2004-07-20.

二级参考文献32

  • 1kelly DF,Richard Moxon E,Pollard AJ. Haemophilus influenzae type b conjugate vaccines. Immunology,2004,113:163-174.
  • 2McVernon J,Andrews N ,Slack MP,et al. Risk of vaccine failure after Haemophilus influenzae type b(Hib)combination vaccines with acellular pertussis. Lancet ,2003,361:1521-1523.
  • 3Makela PH,Kayhty H,Leino T,et al. Long-term persistence of immunity after immunisation with Haemophilus influenzae type b conjugate vaccine. Vaccine, 2003,22: 287-292.
  • 4CDC. Recommendations for use of Haemophilus b conjugate vaccines and combined diphtheria, tetanus, pertussis, and Haemophilus b vaccine: recommendations of the Advisory Committeeon Immunization Practice (ACIP) [J]. MMWR 1993, 42( RR-13) : 1-15.
  • 5Greenberg DP, Wong VK, Partridge S, et al. Immunogenieity of a Haemophilus influenzae type b-tetanus toxoid conjugate vaccine when mixed with a diphtheria-tetanus-acellular pertussis-hepatitis B combination vaeeine[ J]. Pediatr Infect Dis J 2000, 19(12) :1135-1140.
  • 6Omenaca F, Dal-Re R, D'Apuzzo V, et al. Reactogenicity of DTPa-HBV/Hib vaccine administered as a single injection vs DTPa-HBV and Hib vaccines administered simultaneously at separate sites, to infants at 2, 4 and 6 months of age[J]. Vaccine 2001,19(30): 4260-4266.
  • 7Aristegui J, Dal-Re R, Garrote E, et al. Assessment of the immunogenieity and reaetogenieity of a quadrivalent diphtheria, tetanus,acellular pertussis and hepatitis B (DTPa-HBV) vaccine administered in a single injection with Haemophilus influenzae type b conjugate vaccine, to infants at 2, 4 and 6 months of age[ J ]. Vaccine 1998,16(20) : 1976-1981.
  • 8Mills E, Gold R, Thipphawong J, et al. Safety and immunogenicity of a combined five-component pertussis-diphtheria-tetanusinactivated poliomyelitis-Haemophilus b conjugate vaccine administered to infants at two, four and six months of age[ J]. Vaccine 1998, 16: 576-585.
  • 9MB Rennels, GF Reed, MD Decker, et al. Simultaneous administration of Haemophilus influenzae type b vaccine with acellular or whole-cell pertussis vaccine: effects on reactogenicity and immune responses to pertussis vaccines[ J ]. Pediatrics 1995, 96:576-579.
  • 10Hogg K, Hogg G. The immunogenicity of oral poliomyelitis vaccine in a primary vaccination series at 2, 4 and 6 months given concurrently with Hib, hepatitis B and diphtheria, tetanus and whole-cell pertussis vaccines administered as three separate injections or as a combination pentavalent vaccine[J ]. Vaccine 2003,21 (21-22) : 2906-2910.

共引文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部